Neurosurgery in the suburbs: Ascension Illinois added Dr. Tamir Hersonskey to its medical group for neurosurgery, seeing patients at Ascension Alexian Brothers in Elk Grove Village, with expertise ranging from brain/spine tumors to trigeminal neuralgia and chronic low back pain. GLP-1 safety watch: Northwestern Medicine research links GLP-1 starts (semaglutide/tirzepatide/liraglutide) with higher hypotension-related events in people on multiple blood pressure drugs, especially older adults and those with type 2 diabetes. Medication reality check: New data suggests many patients stop GLP-1s within a year, then restart later—more “start-and-stop” than permanent discontinuation. Diabetes and sleep: An ENDO 2026 study ties long naps (over 30 minutes) plus poor nighttime sleep to higher risk of fatty liver disease in people with type 2 diabetes. Food safety: The FDA upgraded an Alfredo sauce recall to the highest risk level over possible Salmonella contamination, affecting distribution including Illinois. Community wellness spotlight: Chicago launches Black Culture Week, promoting “Black Culture Wellness” as a framework connecting culture, health, wealth, and community empowerment. Illinois policy for exonerees: A bill on Gov. JB Pritzker’s desk would raise wrongful imprisonment compensation up to $50,000 per year, plus added amounts for probation/parole/registry time. Local housing concerns: Cook County Commissioner Tara Stamps heard Austin residents’ complaints about rising taxes, rents, and county-owned lots, and promised follow-up with relevant agencies. Health in the air: Corey Feldman was hospitalized after a mid-flight medical emergency on a Chicago-to-LA trip, with early reports pointing to possible pancreatitis or gallstones. Public safety: A police-involved shooting in Uptown sent at least two people to hospitals in serious condition, according to local officials and investigators. Cancer care momentum: ENDO 2026 research and other oncology updates continue to highlight new approaches and outcomes, including promising long-term results in melanoma trials.